New England Peptide launches NEPTune line of custom proteomics reagents

NewsGuard 100/100 Score

New England Peptide (NEP) today introduced NEPTune TM, a new proprietary line of custom proteomics reagents to help its customers to quickly and inexpensively maximize biomarker assay development and produce consistent results.

“In proteomics, reproducibility and robust techniques are paramount, and NEPTuneTM helps our customers overcome these critical hurdles in an efficient and cost-effective manner.”

"Proteomics is an exciting research field that is poised to deliver the next generation of life-changing diagnostic tools and drug therapies," said Dave Robinson, NEP's Chief Executive Officer. "We have great interest in proteomic research and are pleased to be the only company providing this high quality, proprietary line of services to our customers. It marks a revolutionary step forward for NEP and the field of proteomics as a whole."

Proteomics is the large scale study of the set of proteins specified by genes within an organism with the aim to understand how biological systems operate on a fundamental level. Proteomic-based (human) diagnostics and resultant therapies have the potential to allow physicians to treat disease states in a more specific and targeted approach, which will help deliver on the promise of personalized medicine and tailored therapies that have been discussed in the health care industry in recent years.

The NEPTune TM line comprises a suite of four distinct solutions that align with the various needs of proteomics researcher and clinician, ranging from biomarker discovery through clinical assay production:

  • NEPTune™ Assay Discovery Peptides - NEP's technology allows customers to quickly and less inexpensively increase the number of peptides they screen, enabling them to more efficiently reach their research goals.
  • NEPTune™ Assay Verification Peptides - Since proteomics verification is a critical stage in the development of a viable biomarker assay, NEP offers peptide and antibody reagents tailored to complement this phase of the proteomics project lifecycle.
  • NEPTune™ Assay Refinement Peptides - The culmination of rigorous discovery and verification studies has its own unique set of needs, which are met by NEP's assay refinement solution.
  • NEPTune™ Clinical Assay Peptides - NEP already supports many ongoing clinical assays around the world with its reagents.

Robinson noted that NEP has been a leader in proteomics research for years and has assembled a team - led by Chemical Development Vice President Robert Hammer, PhD and Proteomics Product Manager John Antognoni with consultation from NEP's industry-leading scientific advisory board - that delivers the industry's only single source of peptides optimized for quantitative proteomics.

"New England Peptide has been at the forefront of proteomic peptide research for years and the introduction of the NEPTuneTM line allows us to provide even better service to our customers," said Antognoni. "In proteomics, reproducibility and robust techniques are paramount, and NEPTuneTM helps our customers overcome these critical hurdles in an efficient and cost-effective manner."

NEPTuneTM is the latest in a line of proprietary product and process innovations developed by NEP's in-house team. Last December, NEP launched PepScaleTM, a proprietary peptide synthesis instrument, that better enables peptide scale-up and process development projects for its customers. In September, NEP rolled out PepCROTM, the first peptide-focused contract research service for drug, vaccine and diagnostic discovery projects. Last July, NEP unveiled FlashPureTM, the peptide industry's first flash purification system.

Customers interested in the industry's newest set of proteomics services should contact the NEP's business development group at 888-343-5974.

Source:

New England Peptide

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Alzheimer's disease found to have five distinct subtypes